CSPC Pharmaceutical Group Ltd. announced that their drug CPO301 has been granted its third Fast Track designation by the U.S. Food and Drug Administration (FDA). This designation is for the treatment of adult patients with advanced or metastatic non-squamous non-small cell lung cancer (Nsq-NSCLC) without EGFR mutations, who have experienced disease progression following platinum-based chemotherapy and anti-PD-$(L)$1 antibody treatment. This marks the third Fast Track designation for CPO301, following previous designations for other NSCLC treatment contexts. The Fast Track status will aid in expediting the development and registration processes for CPO301 in the U.S. and globally. No other organizations were mentioned in obtaining this grant.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。